Source: Knight Therapeutics LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Knight Therapeutics (GUD) has received approval from the TSX to initiate a normal course issuer bid
  • Knight Therapeutics will purchase up to 10,267,956 common shares of the company over the next 12 months
  • The company may purchase up to a maximum of 80,015 shares per day
  • Knight Therapeutics is a Canadian-based pharmaceutical company
  • Knight Therapeutics Inc. (GUD) opened trading at C$5.22 per share

Knight Therapeutics (GUD) has received approval from the TSX to initiate a normal course issuer bid (NCIB).

Knight Therapeutics will purchase up to 10,267,956 common shares of the company over the next 12 months.

As of June 30, 2021, there were a total of 125,664,970 common shares issued and outstanding. Purchases may commence on July 14, 2021, and will be completed by July 13, 2022.

The company may purchase up to a maximum of 80,015 shares per day. Knight also entered into an automatic share purchase plan with a broker in order to facilitate purchases of its common shares under the NCIB.

Under the company’s automatic share purchase plan, Knight’s broker may repurchase common shares which it would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods. The automatic share purchase plan has been pre-cleared by the TSX and will be implemented as of July 14, 2021.

The price that Knight will pay for common shares in open market transactions will be the market price at the time of purchase.

Knight Therapeutics is a Canadian-based pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America.

Knight Therapeutics Inc. (GUD) opened trading at C$5.22 per share.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.